Clinical Trials | NRG-GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53-Mutated Advanced or Recurrent Endometrial Cancer

The University of Virginia seeks adult women with stage III, IVA, IVB or recurrent endometrial cancer. The goal of this study is to test whether adding bevacizumab to the combination of carboplatin, paclitaxel, and pembrolizumab can better treat advanced or recurrent pMMR and TP53-mutated endometrial cancer, compared to the usual treatment of carboplatin and paclitaxel with or without pembrolizumab. You may be eligible for this study if: - You have stage III, IVA, or IVB endometrial cancer - You have recurrent endometrial cancer (any stage) - You have not received prior chemotherapy for treatment of your endometrial cancer OR you have received prior adjuvant chemotherapy 12 months or longer before enrolling in this study - Your tumor is both mismatch repair proficient (pMMR) and P53 mutated. This study involves blood draws, physical examinations, and tumor imaging examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT07198074